Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dicerna Pharmaceuticals Inc.

www.dicerna.com

Latest From Dicerna Pharmaceuticals Inc.

Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV

With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.

Research & Development Liver & Hepatic

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deals Business Strategies

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash

Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.

Financing Business Strategies

Family Comes First as BI Finance Chief Exits Over Future Direction

The departure of finance chief Simone Menne follows "divergent views" with the board over strategy shows that Boehringer Ingelheim will not countenance any moves that could threaten its independence.

Leadership Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dicerna Pharmaceuticals Inc.
  • Senior Management
  • Douglas C Fambrough, III, PhD, Pres. & CEO
    Jack Green, CFO
    Bob D Brown, PhD, SVP, CSO
    James B Weissman, CBO
  • Contact Info
  • Dicerna Pharmaceuticals Inc.
    Phone: (617) 621-8097
    87 Cambridge Park Dr.
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register